BEAM
Beam Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$26.33-4.36%
Price as of Jul 20, 2026
BEAM profitability
Beam Therapeutics Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -39.2%
- EBITDA margin
- -19.5%
- EBIT margin
- -226.6%
- Net margin
- -39.7%
- Free cash flow margin
- -234.0%
Returns
- Return on equity
- -5.6%
- Return on assets
- -4.4%
- Return on invested capital
- -26.3%
- Asset turnover
- 0.11x
Cash efficiency
- Cash from operations
- -$369.7M
- Cash per share
- $12
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.